Detalles de la búsqueda
1.
Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
Eur J Haematol
; 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38853698
2.
Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.
Cost Eff Resour Alloc
; 22(1): 21, 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459569
3.
Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Eur J Haematol
; 111(6): 895-908, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37644352
4.
Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre.
Mycoses
; 66(5): 405-411, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36670539
5.
Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city.
J Antimicrob Chemother
; 77(3): 753-757, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34849943
6.
A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital.
Infection
; 50(1): 191-201, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34406606
7.
Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier.
Cost Eff Resour Alloc
; 20(1): 67, 2022 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36503527
8.
Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals.
Mycoses
; 64(1): 86-94, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33034927
9.
Reimbursement of innovative pharmaceuticals in English and Spanish hospitals-The example of isavuconazole.
Mycoses
; 64(10): 1213-1222, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34134179
10.
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.
BMC Health Serv Res
; 21(1): 939, 2021 Sep 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496836
11.
Quantifying guideline adherence in mucormycosis management using the EQUAL score.
Mycoses
; 63(4): 343-351, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31876327
12.
Infectious disease services: a survey from four university hospitals in Germany.
Infection
; 47(1): 27-33, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30120718
13.
Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective.
Eur J Haematol
; 98(2): 169-176, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27727474
14.
A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
Eur J Haematol
; 94(6): 526-31, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25310918
15.
Economic effects of treating postpartum hemorrhage with vacuum-induced hemorrhage control devices - A budget impact analysis of the Jada® System in the German obstetrics setting.
Eur J Obstet Gynecol Reprod Biol
; 294: 222-230, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301501
16.
A Retrospective Budget Impact Analysis of Fidaxomicin Treatment for Clostridioides difficile Infections (CDI) in Germany.
Expert Rev Pharmacoecon Outcomes Res
; 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38712561
17.
Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis.
JAC Antimicrob Resist
; 5(3): dlad079, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37342199
18.
Cost Comparison of Treatment Alternatives for Pleural Effusion and Ascites from a Payer Perspective: Are There Cost Savings from Indwelling Catheters?
J Palliat Med
; 26(11): 1510-1520, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37352428
19.
Health Economic Aspects of Platelet Concentrates: Comparing Cost and Reimbursement of Pathogen Inactivated and Conventional Platelet Concentrates in a German Comprehensive Cancer Center.
Oncol Res Treat
; 46(9): 362-369, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37482056
20.
Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis.
J Infect Public Health
; 16(6): 955-963, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37099955